Clinical heterogeneity, unpredictable course and flares are characteristics of systemic lupus
erythematosus (SLE). Although SLE is—by and large—a systemic disease, occasionally it …

Systemic lupus erythematosus (SLE) is a devastating autoimmune disease that can result in
substantial morbidity and mortality. Diagnosis and treatment of SLE are clinical challenges …

Glomerular disease, be it primary or secondary, occurring in the setting of systemic
autoimmune diseases, infections, drugs, or malignancy, affects individuals of all ages. In …

Background Voclosporin, a novel calcineurin inhibitor approved for the treatment of adults
with lupus nephritis, improved complete renal response rates in patients with lupus nephritis …

Objectives To update the EULAR recommendations for the management of systemic lupus
erythematosus (SLE) based on emerging new evidence. Methods An international Task …

Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed
to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a …

Objective To assess the efficacy and safety of the type I interferon receptor antibody,
anifrolumab, in patients with active, biopsy-proven, Class III/IV lupus nephritis. Methods This …

We performed a post hoc analysis of the Belimumab International Study in Lupus Nephritis
(BLISS-LN), a Phase 3, multinational, double-blind, 104-week trial, in which 448 patients …

Objective AURORA 2 evaluated the long‐term safety, tolerability, and efficacy of voclosporin
compared to placebo in patients with lupus nephritis (LN) receiving an additional two years …

Systemic lupus erythematosus (SLE) is a chronic multifactorial autoimmune disease that
affects many organs, including the kidney. Lupus nephritis (LN) is a common manifestation …